Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow
All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free Survival
Clinical-scale Production of FT500 Off-the-Shelf NK Cell Cancer Immunotherapy Initiated in Support of Landmark IND Filing
Breakthrough Generation of Universal CAR T cells from Clonal Master iPSC Line Achieved under MSK Collaboration
Preclinical Data of FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrate Target-specific Anti-tumor Activity
“Initial clinical observations from the investigation of our first-in-class product candidates have established
Clinical Programs – Highlights & Updates
- Anti-Leukemia Activity of FATE-NK100 Observed in VOYAGE Study. In
November 2017, initial clinical data of FATE-NK100, a first-in-class adaptive memory natural killer (NK) cell product, from the ongoing VOYAGE study for the treatment of refractory or relapsed acute myelogenous leukemia (AML) were presented at the Society for Immunotherapy of CancerAnnual Meeting. At two weeks following a single intravenous infusion of FATE-NK100, the subject in the first dose cohort showed nearly a 50% reduction in leukemic blasts and the subject in the second dose cohort achieved a morphologic leukemia-free state based on bone marrow biopsy.No dose limiting toxicities were reported.
- Advanced FATE-NK100 through First Two Dose Cohorts of APOLLO Study. In
December 2017, the APOLLO study of FATE-NK100 was initiated for the treatment of women with ovarian cancer that is resistant to, or recurrent on, platinum-based treatment. FATE-NK100 has advanced through the first two dose cohorts with no reports of dose limiting toxicities. The Company expects to release initial clinical data from the ongoing APOLLO study at the 3rd Innate Killer Summit ( March 27-29, San Diego).
- Reported Day 100 Clinical Data from Phase 1 Stage of PROTECT Study of ProTmune™. In
December 2017, initial clinical data of ProTmune, a next-generation hematopoietic cell graft, were presented at the 59th American Society of Hematology(ASH) Annual Meeting and Exposition. During the first 100 days following hematopoietic cell transplantation (HCT), all seven subjects receiving ProTmune in the Phase 1 stage of the PROTECT study for the treatment of hematologic malignancies remained alive and relapse-free. Three subjects experienced acute graft-versus-host disease (GvHD) during the first 100 days following HCT, all of whom responded to standard-of-care steroid treatment. There were no ProTmune-related serious adverse events reported by investigators.
Preclinical Programs – Highlights & Updates
- Initiated IND-enabling Manufacture of FT500 iPSC-derived NK Cell Cancer Immunotherapy. Clinical-scale production of FT500, a first-of-kind, off-the-shelf NK cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line, commenced at Molecular and Cellular Therapeutics, a state-of-the-art,
FDA-registered Good Manufacturing Practice (GMP) facility. The Company is currently preparing an Investigational New Drug (IND) application for FT500 for submission to the U.S. Food and Drug Administration( FDA) in the first half of 2018. The Company plans to clinically investigate multiple dosing cycles of FT500 in combination with FDA-approved checkpoint inhibitor therapy for the treatment of advanced solid tumors.
- Presented Preclinical Data for FT819 iPSC-derived CAR19 T-Cell Cancer Immunotherapy. In
December 2017, scientists from the laboratories of Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, and Fate Therapeuticspresented at ASH the generation of iPSC-derived, anti-CD19 chimeric antigen receptor (CAR)-targeted, TCR-null CD8αβ+ T cells. The universal T cells were derived from a single iPSC engineered to completely eliminate T-cell receptor (TCR) expression and to insert a CAR targeting CD19 into the T-cell receptor α constant ( TRAC) locus. The groundbreaking development enables the renewable production of large quantities of CAR T cells, from a clonal master iPSC line, that are uniformly engineered and are not patient-restricted. In preclinical studies, the collaborators demonstrated that the universal CAR T cells displayed target-specificity and potent anti-tumor activity. Fate Therapeuticsis currently advancing FT819, an off-the-shelf CAR19 T-cell product candidate derived from a clonal master iPSC line engineered with complete TCR elimination and TRAC-regulated CAR expression.
- Launched Collaboration with UCSD for Development of iPSC-derived CAR NK Cell Cancer Immunotherapies. The multi-year research collaboration with the
University of California, San Diego(UCSD) is being led by Dan S. Kaufman, M.D., Ph.D., Professor of Medicine in the Division of Regenerative Medicineand Director of Cell Therapy. Dr. Kaufman and Fate Therapeuticshave developed a novel CAR construct specifically designed to enhance NK cell activation and persistence that is comprised of a NKG2D transmembrane domain, a 2B4 co-stimulatory domain and a CD3ζ signaling domain. Preclinical data presented at ASH demonstrated that a single dose of these iPSC-derived CAR NK cells markedly inhibited tumor growth and significantly enhanced survival as compared to iPSC-derived CAR NK cells containing a construct commonly used in T cells.
Fourth Quarter 2017 Financial Results
- Cash & Short-term Investment Position: Cash, cash equivalents and short-term investments as of
December 31, 2017were $100.9 millioncompared to $92.1 millionas of December 31, 2016. The increase was primarily driven by $43.2 millionin net cash proceeds received by the Company from its December 2017public offering of common stock and $7.5 millionin net cash proceeds received by the Company in July 2017in connection with the amendment of its loan agreement with Silicon Valley Bank. These proceeds were offset by the Company’s use of cash to fund operating activities and to service principal and interest obligations under its loan agreement with Silicon Valley Bank.
- Total Revenue: Revenue was
$1.0 millionfor the fourth quarter of 2017 as well as for the comparable period in 2016. All revenue was derived from the Company’s research collaboration and license agreement with Juno Therapeutics.
- Total Operating Expenses: Total operating expenses were
$13.3 millionfor the fourth quarter of 2017 compared to $8.7 millionfor the comparable period in 2016. Operating expenses for the fourth quarter of 2017 included $0.9 millionof stock compensation expense compared to $0.8 millionfor the comparable period in 2016.
- R&D Expenses: Research and development expenses were
$9.9 millionfor the fourth quarter of 2017 compared to $6.2 millionfor the comparable period in 2016. The increase in R&D expenses was attributable to an increase in third-party service provider fees for the manufacture and clinical development of ProTmune and FATE-NK100 and for FT500 IND-enabling activities, as well as an increase in equipment and materials associated with the advancement of the Company’s iPSC-derived cancer immunotherapy programs, employee compensation and benefits expense, and facilities costs associated with the expansion of the Company’s laboratory space.
- G&A Expenses: General and administrative expenses were
$3.4 millionfor the fourth quarter of 2017 compared to $2.5 millionfor the comparable period in 2016. The increase in G&A expenses was attributable to an increase in intellectual property-related expenses and licensing costs.
- Shares Outstanding: Common shares outstanding were 52.6 million as of
December 31, 2017and 41.4 million as of December 31, 2016. Preferred shares outstanding as of December 31, 2017and December 31, 2016were 2.82 million, each of which is convertible into five shares of common stock. All preferred shares outstanding are from the Company’s sale and issuance of non-voting Class A convertible preferred stock to Redmile Group, LLCin November 2016.
Today's Conference Call and Webcast
The Company will conduct a conference call today,
FATE-NK100 is a first-in-class, allogeneic donor-derived natural killer (NK) cell cancer immunotherapy comprised of adaptive memory NK cells, a highly specialized and functionally distinct subset of activated NK cells expressing the maturation marker CD57. Higher frequencies of CD57+ NK cells in the peripheral blood or tumor microenvironment in cancer patients have been linked to better clinical outcomes. In
ProTmune™ is an investigational next-generation hematopoietic cell graft for the prevention of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). ProTmune is manufactured by pharmacologically modulating a donor-sourced, mobilized peripheral blood graft ex vivo with two small molecules (FT1050 and FT4145) to decrease the incidence and severity of acute GvHD while maintaining the anti-leukemia activity of the graft. ProTmune has been granted Orphan Drug and Fast Track Designations by the
About Fate Therapeutics’ iPSC Product Platform
The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables large-scale generation of off-the-shelf, engineered, homogeneous cell products that can be administered in repeat doses to mediate more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event, and selecting a single iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for consistently and repeatedly manufacturing homogeneous cell products in quantities that support the treatment of many thousands of patients in an off-the-shelf manner. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 90 issued patents and 100 pending patent applications.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company’s advancement of and plans related to its product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for its manufacture and clinical investigation of ProTmune™ and FATE-NK100 and its manufacture, preclinical development and clinical investigation of its iPSC-derived product candidates, the Company’s receipt of data from its clinical trials and preclinical studies, the Company’s development and regulatory strategy, including the therapeutic and market potential, for its product candidates, and the Company’s financial condition and projected cash expenditures. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of its product candidates, including preclinical studies and clinical trials of ProTmune and FATE-NK100, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay in the enrollment or evaluation of subjects in any clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties or delays in subject enrollment in current and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that the Company’s expenditures may exceed current expectations for a variety of reasons. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the
Availability of Other Information about
Investors and others should note that the Company routinely communicates with investors and the public using its website (www.fatetherapeutics.com) and its investor relations website (ir.fatetherapeutics.com) including, without limitation, through the posting of investor presentations,
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
|Three Months Ended||Years Ended|
|December 31,||December 31,|
|Research and development||9,887||6,230||34,358||26,452|
|General and administrative||3,384||2,451||11,873||9,913|
|Total operating expenses||13,271||8,681||46,231||36,365|
|Loss from operations||(12,244||)||(7,654||)||(42,125||)||(31,963||)|
|Other income (expense):|
|Loss on extinguishment of debt||—||—||(118||)||—|
|Total other expense, net||(253||)||(286||)||(827||)||(1,499||)|
|Other comprehensive income (loss):|
|Unrealized gain (loss) on available-for-sale securities, net||10||(4||)||(2||)||(1||)|
|Net loss per common share, basic and diluted||$||(0.29||)||$||(0.21||)||$||(1.02||)||$||(1.05||)|
|Weighted–average common shares used to
compute basic and diluted net loss per share
Condensed Consolidated Balance Sheets
|December 31,||December 31,|
|Cash and cash equivalents||$||88,952||$||88,609|
|Short-term investments and related maturity receivables||11,997||3,503|
|Prepaid expenses and other current assets||1,647||1,211|
|Total current assets||102,596||93,323|
|Liabilities and stockholders’ equity|
|Accounts payable and accrued expenses||$||8,932||$||4,891|
|Long-term debt, current portion||—||8,187|
|Current portion of deferred revenue||2,105||2,105|
|Other current liabilities||12||4|
|Total current liabilities||11,049||15,187|
|Long-term debt, net of current portion||14,808||2,501|
|Other long-term liabilities||1,522||1,377|
|Total liabilities and stockholders’ equity||$||105,292||$||95,048|
Stern Investor Relations, Inc.
Source: Fate Therapeutics, Inc.